Furthermore,
hydroxychloroquine 200 mg uses has garnered attention for its potential role in mitigating immune-mediated damage in organ transplantation. In solid organ transplantation, the risk of rejection poses a significant challenge despite advancements in immunosuppressive therapies. Plaquenil's immunomodulatory effects may offer an adjunctive strategy to prevent allograft rejection and promote transplant tolerance, potentially reducing the reliance on traditional immunosuppressive agents with their associated adverse effects. Clinical trials exploring Plaquenil-based immunosuppression regimens in transplantation settings hold promise for improving graft outcomes and long-term patient survival, highlighting its evolving role in transplant medicine.
